Inovalon Launches AI-Powered Tool to Streamline Clinical Trial Recruitment — Inovalon Holdings, Inc.

Event summary

Inovalon launched Clinical Trial Eligibility Screener™ on January 20, 2026.
The API uses NLP to evaluate patient eligibility against study-specific criteria in real time.
Service integrates with existing recruitment platforms to reduce manual pre-screening.
Inovalon ONE® Platform supports over 50,000 active customers and processes data from 451 million unique lives.

The big picture

Inovalon's new tool addresses a critical bottleneck in clinical research, where two-thirds of sites miss enrollment targets. By leveraging its vast data network and NLP capabilities, the company aims to set a new standard for patient identification and trial execution. The move underscores the growing importance of AI-driven solutions in accelerating drug development timelines.

What we're watching

Adoption Pace: How quickly sponsors and CROs integrate the screener into existing workflows.
Efficiency Gains: Whether real-time eligibility assessments significantly reduce trial timelines.
Competitive Response: How competitors in clinical trial recruitment technology react to this innovation.